MS patients switch meds: will it change their disease?
NCT ID NCT07235644
First seen Nov 19, 2025 · Last updated Jun 06, 2026 · Updated 32 times
Summary
This study looks at people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar drug called Rixathon. Researchers want to see if the switch causes any changes in nerve damage, brain lesions, relapses, or disability. The study uses health data already collected from 184 patients at Uppsala University Hospital.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uppsala University Hospital
Uppsala, Sweden
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.